Hemotrex

Tablet: Tranexamic acid is an antifibrinolytic agent used mainly in the treatment and prophylaxis of hemorrhage associated with excessive fibrinolytic. It is given by mouth or by slow IV injection, limited due to gastrointestinal disturbances; hypotension has occurred, particularly after rapid IV infusion.
Pharmacokinetics: Tranexamic acid is rapidly absorbed from the gastrointestinal tract: absorption is 30-50%. It is widely distributed throughout the body, diffuses across the placenta and has been detected in breast milk. It has a plasma elimination half-life of about 2 hrs. It is excreted in the urine mainly as unchanged drug.

Treatment and prophylaxis of hemorrhage associated with excessive fibrinolysis. It is also used in the prophylaxis of hereditary angioedema.
Injection: Treatment and prophylaxis of hemorrhage associated with general excessive fibrinolysis (leukemia, aplastic anemia, purpura, pre- and postoperative hemorrhage) and with local excessive fibrinolysis (pneumorrhagia, genital bleeding, renal bleeding, pre- and postoperative hemorrhage following prostatectomy).

Tablet: 1-1.5 g (15-25 mg/kg body weight) 2-4 times daily. Hereditary Angioedema: Tranexamic acid given to prolonged periods in doses of 1-1.5 g by mouth 2-3 times a day, or as prescribed by the physician.
Injection: When given by slow IV injection, doses are 0.5-1 g (or 10-15 mg/kg) 3 times daily. Tranexamic acid is administered by continuous infusion at a rate of 25-50 mg/kg daily.

Patients with active intravascular clotting because of the risk of thrombosis. Patients with a predisposition to thrombosis are also at risk if given antifibrinolytic therapy. Hemorrhage due to disseminated intravascular coagulation should, therefore, not be treated with antifibrinolytic compounds unless the condition is predominantly due to disturbances in fibrinolytic mechanisms; tranexamic acid has been used when the latter conditions are met but with monitoring and anticoagulant cover.

Injection: Hypersensitivity to Hemotrex.
Patients with thrombolism (cerebral thrombosis, myocardial infarction, thrombophlebitis) or at risk of thromboembolic disease.
Patients with marantic coagulopathy (heparin should be concomitantly used).
The drug is slowly administered IV (rapid IV administration may rarely be associated with nausea, discomfort of chest, palpitation or hypotension).

Tablet: Tranexamic acid appears to be well tolerated. It can produce dose-related gastrointestinal disturbances. Hypotension has occurred particularly after rapid IV administration. Thrombotic complications have been reported in patients receiving tranexamic acid but these are usually the consequences of its appropriate use.
Injection: Hypersensitivity: The administration should be discontinued if signs and symptoms of hypersensitivities appear.
Dermatological: Pruritus or eruption may rarely occur.
Ocular: Disturbance of color vision, although rarely, may occur following IV administration of Hemotrex.
Shock: Hemotrex may, although rarely, cause shock. Therefore, the patients should be carefully observed during therapy. If any symptoms occur, the administration should be discontinued and appropriate therapy should be instituted.
Others: Drowsiness or headache may rarely occur.

Injection: Caution is required when administering Hemotrex concomitantly with hemocoagulase because such combination in large doses may increase the potential for thrombus formation.
Others: Long-term administration of large dose of Hemotrex has been reported to be associated with change in retina in dogs.
Hemotrix has been reported to be incompatible with following drugs given by injection; reserpine, methyl and ethyl testosterone, lipid and tissue thromboplastin, sulfadimethoxine.
Some animal studies have shown that concomitant IV administration of Hemotrex with lipid thromboplastin in large doses has caused thrombus formation.

Store at temperatures not exceeding 30°C.
Shelf-Life: Tablet: 36 months.

Haemostatics

B02AA02 - tranexamic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.

Rx